Future Possibilities for CAR T Cells in Non-Hodgkin's Lymphoma

Video

Miguel-Angel Perales, MD, deputy chief of Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center, discusses what experts are expecting to change in the treatment landscape of non-Hodgkin’s lymphoma in the next year. Perales says by the end of 2018, there may be 3 CAR T-cell therapies approved for the treatment of non-Hodgkin’s lymphoma.

Miguel-Angel Perales, MD, deputy chief of Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center, discusses what experts are expecting to change in the treatment landscape of non-Hodgkin’s lymphoma in the next year. Perales says by the end of 2018, there may be 3 CAR T-cell therapies approved for the treatment of non-Hodgkin’s lymphoma, and physicians will have options when treating their patients.

In 2017, a new CAR T-cell therapy, axicabtagene ciloleucel (Yescarta), was approved by the FDA for the treatment of patients with non-Hodgkin’s lymphoma. Based on results from the JULIET and TRANSCEND trials, Perales expects that 2 new CAR T-cell agents may also be approved in 2018.

Related Videos
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Hannah Choe, MD, an expert on GVHD
Corey Cutler, MD, MPH, an expert on GVHD
Related Content